Klivira
Request demo

Streamlining Medicare Entyvio Prior Authorization Workflows

Navigating **Medicare Entyvio prior authorization** requires precise understanding of both Original Medicare and Medicare Advantage plan requirements. Klivira streamlines this process, ensuring accurate submissions and reducing administrative overhead.

For revenue cycle directors and prior authorization coordinators, managing high-volume specialty drug PAs like Entyvio can be a significant operational challenge. The diverse requirements across Medicare's various programs—Original Medicare (Part B) and Medicare Advantage—demand a sophisticated approach to avoid delays and denials. Klivira provides the automation and intelligence needed to navigate these complexities efficiently.

Entyvio (Vedolizumab) in the Medicare Context

Entyvio (vedolizumab) is an alpha4beta7 integrin inhibitor indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adult patients. As a high-cost specialty biologic administered via intravenous infusion, it is typically covered under Medicare Part B. Prior authorization is consistently required to ensure medical necessity and adherence to coverage criteria for this high-volume medication.

Prior Authorization Channels for Entyvio Under Medicare

The specific prior authorization pathway for Entyvio depends heavily on the Medicare program. For Original Medicare (Part B), where PA is required, submissions are routed through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. Medicare Advantage (MA) plans, however, operate with broader PA requirements, often mirroring commercial plan processes and utilizing their own portals and X12 278 submission channels.

Navigating Original Medicare (Part B) Prior Authorization for Entyvio

While Original Medicare has a limited scope for prior authorization, specific programs or high-cost infusions like Entyvio may fall under MAC review. Klivira's platform is equipped to handle per-jurisdiction submission specifics for MACs such as Noridian, NGS, WPS, Palmetto, FCSO, and Novitas. This ensures that even in the narrower context of Original Medicare PA, submissions are accurate and compliant with local coverage policies.

Entyvio Prior Authorization in Medicare Advantage Plans

Medicare Advantage (MA) plans, offered by private insurers, typically have more extensive prior authorization requirements for specialty drugs like Entyvio compared to Original Medicare. These plans often incorporate step therapy, quantity limits, and specific formulary tiers. Klivira's platform integrates with the diverse portals and X12 278 submission channels used by MA plans, automating the capture of plan-specific requirements and facilitating efficient submission.

Policy Adherence and Denial Prevention for Entyvio

Successful Entyvio prior authorization hinges on strict adherence to payer-specific medical policies. For Original Medicare, this means aligning with National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) published by the responsible MAC. Medicare Advantage plans develop their own utilization management policies. Klivira's intelligent routing incorporates NCD/LCD-aware logic and payer-specific policy libraries to proactively identify and mitigate common denial reasons, such as insufficient documentation or failure to meet step-therapy criteria.

Frequently asked questions

How does Klivira handle Entyvio prior authorization for Original Medicare versus Medicare Advantage?

For Original Medicare (Part B), Klivira routes Entyvio PA requests through the appropriate Medicare Administrative Contractor (MAC) based on jurisdiction, adhering to NCDs and LCDs. For Medicare Advantage plans, Klivira connects with the private insurer's specific portals and submission channels, navigating their often broader PA requirements, including step therapy and quantity limits.

What are common reasons for Entyvio PA denials under Medicare?

Common denial reasons include insufficient clinical documentation to support medical necessity, failure to meet step-therapy requirements (primarily with MA plans), or missing specific NCD/LCD criteria for Original Medicare. Klivira helps prevent these by ensuring submissions are complete and aligned with payer policies before submission.

Does Entyvio require prior authorization for all Medicare beneficiaries?

Prior authorization for Entyvio is highly common for both Original Medicare (Part B) and virtually all Medicare Advantage plans due to its high cost and specialty nature. While Original Medicare's PA scope is generally narrower, high-cost infusions like Entyvio are frequently subject to review by MACs or MA plans.

How does Klivira access Medicare's coverage policies for Entyvio?

Klivira integrates access to CMS's National Coverage Determinations (NCDs) and relevant Local Coverage Determinations (LCDs published by MACs) for Original Medicare. For Medicare Advantage plans, our system connects to the specific plan's policy libraries, ensuring up-to-date adherence to their utilization management criteria for drugs like Entyvio.

Which MACs does Klivira support for Entyvio prior authorizations?

Klivira supports all major Medicare Administrative Contractors (MACs) relevant to Entyvio prior authorizations, including Noridian, NGS, WPS, Palmetto, FCSO, and Novitas. Our platform is designed to handle the specific submission protocols for each MAC jurisdiction, ensuring accurate and timely processing.

Related coverage

Other entyvio prior authorization by payer

Other entyvio prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo